相关临床试验
2
2 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
2
100.0%
暂无批准数据
- Professor Kenji Osafune founded Rege Nephro Co., Ltd. in 2019 to develop iPS cell-based therapies for intractable kidney diseases after pharmaceutical partnership limitations. - The company's nephron progenitor cell therapy has demonstrated kidney-protective effects in mice, with a single administration potentially delaying dialysis by several years. - A novel drug candidate for autosomal dominant polycystic kidney disease entered clinical trials in April 2024, with cell therapy trials for kidney disease targeted for 2027. - Rege Nephro is also advancing iPS cell-derived therapies for diabetes, liver cirrhosis, and metabolic dysfunction–associated steatohepatitis, aiming ultimately to generate whole transplantable organs.
- Rege Nephro has successfully raised $22.5 billion yen ($150 million) in Series B funding to advance clinical trials for kidney disease therapies. - The funding will support Phase II trials of RN-014, a retinoic acid receptor agonist, for Autosomal Dominant Polycystic Kidney Disease (ADPKD) and preparations for US trials. - Funds will also facilitate preclinical trials for RN-032, a cell therapy targeting Chronic Kidney Disease (CKD) using nephron progenitor cells. - The investment underscores confidence in Rege Nephro's iPSC-based technology and its potential to address unmet needs in kidney disease treatment.
